Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BAY1128688 in Healthy Women
NCT02434640Phase 1Completed
- Sponsor
- Bayer
- Start
- Apr 2015
- Primary completion
- Dec 2015
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BAY1128688 in endometriosis (5 arms), sponsored by Bayer. Primary endpoints: Treatment Emergent Adverse Events up to 2 months, Maximum Concentration after Multiple Dose at 24 hours and 1 more. Started Apr 2015; status: completed.
02
Drugs
BAY1128688
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT02434640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02434640.